RAFF2

RAFF2

Ian Stiell and colleagues are back at it with atrial fibrillation; The RAFF2 trial (Electrical versus Chemical cardioversion for Emergency Department patients with Atrial Fibrillation (RAFF2); A partial factorial randomized trial) was published in The Lancet this week.

Acute atrial fibrillation is an irregular dysrhythmia that should be treated within 48 hours to avoid significant complications such as stroke and heart failure. It has a significant epidemiological impact, accounting for about 430,000 ED visits every year in Canada and the United States.

Methods

This large, randomized controlled trial consisted of two protocols, with the first protocol examining cardioversion with IV Procainamide followed by electrical cardioversion if necessary, versus placebo infusion followed by electrical cardioversion. The second protocol was for those who underwent electrical cardioversion; they were subsequently randomized to Anteroposterior versus Anterolateral pad placement during cardioversion.

During this study, 396 patients with acute atrial fibrillation were recruited from 11 Canadian EDs, with a primary outcome of return to normal sinus rhythm for at least 30 minutes following cardioversion.

Outcomes

In the shock-only group (192 patients):

  • 92 percent returned to normal sinus rhythm (176)
  • 95 percent were discharged home (183)

In the drug-then-shock group (204 patients):

  • 96 percent returned to normal sinus rhythm (196)
  • 97 percent were discharged home (198)
  • 52 percent returned to normal sinus rhythm with just Procainamide (106)

Ultimately, both methods of cardioversion were as effective and equally safe for restoring normal sinus rhythm and facilitating discharge from the ED. There were no adverse events or serious side-effects for any patients in this study. No patients were lost to follow up, and at two weeks post-discharge, 95% of patients remained in sinus rhythm.

Notably, over half of the patients who received IV Procainamide cardioverted without requiring a resource-intensive electrical cardioversion; “If I have a patient on a drug infusion, I can see other patients at the same time,” said Dr. Jeffrey Perry, study author and senior scientist at The Ottawa Hospital and professor at the University of Ottawa. “To do electrical cardioversion, I need to find another doctor, a nurse, and a respiratory therapist, and it takes time to assemble those people.”

The researchers note that patients often have a strong preference for one kind of cardioversion, especially if they need it done regularly.

“While we believe that there are advantages to trying the drug infusion before the shock, the treatment choice is ultimately a shared decision between patient and physician,” said Dr. Perry.

This study demonstrates that rhythm control is safe and effective in the Emergency Department, hopefully helping to encourage rhythm control over rate control in these patients.

“We’re excited to support research into treatment methods that help patients quickly return to their normal activities and avoid extended stays in hospitals,” said Dr. Brian Rowe, study co-author and Scientific Director of the Canadian Institutes of Health Research Institute of Circulatory and Respiratory Health, and professor at the University of Alberta.

Shahbaz Syed
Dr. Syed is an staff Emergency physician at the Ottawa Hospital, with an fellowship in Digital Scholarship and special interests in rational resource utilization.
Ian Stiell

Ian Stiell

Dr. Ian Stiell is an Emergency Physician and Senior Scientist at the Ottawa Hospital Research Institute, University of Ottawa and Distinguished Professor.